THERAPY DOSSIER · th-beafebee1082

m-Trifluoromethyl-diphenyl diselenide [(m-CF3-PhSe)2]

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26025319 ↗2015Reported benefit

m-Trifluoromethyl-diphenyl diselenide, a multi-target selenium compound, prevented mechanical allodynia and depressive-like behavior in a mouse comorbid pain and depression model.

MouseOtherMaleIntragastric (i.g.)Acute 0.1 to 10 mg/kg; subchronic 0.1 mg/kgAcute dosing after PSNL; subchronic dosing during the third and fourth weeks af…

Model: Partial sciatic nerve ligation (PSNL) over 4 weeks, comorbid neuropathic pain and depression

Both acute and subchronic treatment prevented PSNL-induced mechanical allodynia and depressive-like behaviour, with subchronic dosing most effective; effects associated with reduced inflammatory signalling and increased BDNF.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…